ASCO

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Adoptive T-Cell Therapy for Cervical Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Pembrolizumab (MK-3745) in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Concurrent Treatment of Advanced Melanoma with Ipilimumab and Nivolumab

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Ipilimumab for Initial Treatment of Metastatic Uveal Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab Combined with Ipilimumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Gefitinib Plus Carboplatin/Pemetrexed as First-Line Therapy of EGFR+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

First-Line Nivolumab Monotherapy in Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Page 11 of 19

8
9
10
11
12
13
14